Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enhancers define a proliferative PGC-1a-expressing melanoma subgroup sensitive to BET inhibition)
By a News Reporter-Staff News Editor at Cancer Weekly -- Researchers detail new data in Oncology - Melanoma. According to news reporting from Berlin, Germany, by NewsRx journalists, research stated, "Metabolic changes are linked to epigenetic reprogramming and play important roles in several tumor types. PGC-1a is a transcriptional coactivator controlling mitochondrial biogenesis and is linked to oxidative phosphorylation."
The news correspondents obtained a quote from the research from Bayer, "We provide evidence that melanoma models with elevated PGC-1a levels are characteristic of the proliferative phenotype and are sensitive to bromodomain and extra-terminal domain (BET) inhibitor treatment. A super-enhancer region highly occupied by the BET family member BRD4 was identified for the PGC-1a gene. BET inhibitor treatment prevented this interaction, leading to a dramatic reduction of PGC-1a expression. Accordingly, BET inhibition diminished respiration and mitochondrial function in cells. In vivo, melanoma models with high PGC-1a expression strongly responded to BET inhibition by reduction of PGC-1a and impaired tumor growth."
According to the news reporters, the research concluded: "Altogether, our findings identify epigenetic regulatory elements that define a subset of melanomas with high sensitivity to BET inhibition, which opens up the opportunity to define melanoma patients most likely to respond to this treatment, depending on their tumor characteristics.Oncogene advance online publication, 9 October."
For more information on this research see: Super-enhancers define a proliferative PGC-1a-expressing melanoma subgroup sensitive to BET inhibition. Oncogene, 2017;():. (Nature Publishing Group - www.nature.com/; Oncogene - www.nature.com/onc/)
Our news journalists report that additional information may be obtained by contacting K.A. Gelato, Drug Discovery, Bayer AG, Berlin, Germany. Additional authors for this research include L. Schockel, O. Klingbeil, T. Ruckert, R. Lesche, J. Toedling, E. Kalfon, M. Heroult, P. Lejeune, U. Monning, A.E. Fernandez-Montalvan, S. Baurle, S. Siegel and B. Haendler (see also Oncology - Melanoma).
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1038/onc.2017.325. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: Berlin, Europe, Germany, Melanoma, Oncology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC